Cerclage in singleton pregnancies with no prior spontaneous PTB and short cervix: a randomized controlled trial.

IF 3.8 2区 医学 Q1 OBSTETRICS & GYNECOLOGY American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-01-27 DOI:10.1016/j.ajogmf.2025.101602
Rupsa C Boelig, Chiara Tersigni, Nicoletta Di Simone, Gabriele Saccone, Fabio Facchinetti, Giovanni Scambia, Vincenzo Berghella
{"title":"Cerclage in singleton pregnancies with no prior spontaneous PTB and short cervix: a randomized controlled trial.","authors":"Rupsa C Boelig, Chiara Tersigni, Nicoletta Di Simone, Gabriele Saccone, Fabio Facchinetti, Giovanni Scambia, Vincenzo Berghella","doi":"10.1016/j.ajogmf.2025.101602","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>PTB (PTB) remains a leading cause of neonatal morbidity and mortality. Cerclage for short cervical length (CL) ≤25mm in singletons with a history of spontaneous PTB is associated with decreased neonatal morbidity/mortality. Both vaginal progesterone and cerclage individually have level 1 evidence supporting benefit in prevention of PTB in pregnancies complicated by short CL, however there is a paucity of level 1 evidence regarding the potential benefit of cerclage with progesterone compared to progesterone alone for short CL ≤25mm in singletons without a history of spontaneous PTB.</p><p><strong>Objective: </strong>We aimed to conduct a pragmatic randomized controlled trial to evaluate the additional benefit of cerclage with vaginal progesterone compared to vaginal progesterone alone in singletons without prior spontaneous PTB and with a current mid-trimester transvaginal ultrasound (TVU) CL ≤25mm STUDY DESIGN: This is a multicenter international randomized controlled trial from 09/2017-09/2023 with four sites in the United States and Italy. Singleton pregnancies without prior spontaneous PTB received TVUCL (universal) screening during mid-trimester anatomy ultrasound as part of routine care. Inclusion criteria was TVUCL≤25mm at 18 0/7 - 23 6/7 weeks. Exclusion criteria included current or planned cerclage, cervical dilation, symptoms of labor, infection, bleeding, rupture of membranes at screening. Participants were randomized 1:1 to cerclage with vaginal progesterone (200mg vaginal progesterone daily) or vaginal progesterone alone; randomization was stratified by study site and TVUCL≤15mm. Primary outcome was PTB<35 weeks by intention to treat analysis. Secondary outcomes included PTB <37,32,28,24 weeks, gestational age at delivery, latency to delivery, and neonatal outcomes. Categorical variables were compared with Pearson Chi-Square and relative risk (RR) estimate and 95% confidence interval (CI). Continuous variables compared with Mann Whitney U test. Latency to delivery and gestational age at delivery were also compared with Kaplan Meier Survival Curve. Planned enrollment was N=206 based on an estimated 0.54 relative risk with cerclage and a 34% incidence of PTB with standard care. The trial was registered on clinicaltrials.gov (NCT03251729) on June 22, 2017.</p><p><strong>Results: </strong>Enrollment ran from September 22<sup>nd</sup>, 2017- October 31<sup>st</sup>, 2023, and it was halted early due to lagging enrollment. Ninety-three participants were randomized, three were excluded due to withdrawal (n=1) and loss to follow up (n=2). Of the 90 included in the intention to treat analysis, 43 to cerclage and progesterone, and 47 to progesterone alone. Overall, 40 (40.4%) had a TVUCL≤15mm. There was no significant difference in primary outcome PTB<35 weeks in those randomized to cerclage with progesterone vs progesterone alone: 16.3% vs 23.4%, RR 0.70 (0.30-1.63). Those randomized to cerclage with progesterone had significantly increased latency from randomization to delivery, median difference 13 (5-20) days (p=0.01), and a significantly later gestational age at delivery, median difference 1.0 (0.2-1.7) weeks (p=0.035). Kaplan Meier Survival curve also demonstrated increased latency to delivery and gestational age at delivery for cerclage with progesterone compared to progesterone alone, Mantel Cox Log Rank p<0.001 and p=0.003 respectively. These findings persisted within both subgroups of ≤15mm and at 16-25mm.</p><p><strong>Conclusion: </strong>In singleton gestations without a prior spontaneous PTB, and a TVU CL ≤25mm before 24 weeks, cerclage with progesterone was not found to significantly reduce PTB rate, but did result in a significantly longer latency from randomization to delivery, and a significantly later gestational age at delivery, compared to progesterone alone. These results suggest the potential for benefit with cerclage and progesterone compared to progesterone alone in singletons without a prior spontaneous PTB and a short cervical length ≤25mm before 24 weeks. This trial was halted early and these findings should be confirmed in larger trial or meta-analysis.</p><p><strong>Tweetable abstract: </strong>In singletons with short cervix and no prior spontaneous PTB cerclage with progesterone compared to progesterone alone did not reduce incidence of PTB; but those with cerclage and progesterone had increased latency to delivery and gestational age of delivery. This trial was halted early, and larger clinical trials or meta-analyses are necessary.</p>","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":" ","pages":"101602"},"PeriodicalIF":3.8000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Obstetrics & Gynecology Mfm","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajogmf.2025.101602","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: PTB (PTB) remains a leading cause of neonatal morbidity and mortality. Cerclage for short cervical length (CL) ≤25mm in singletons with a history of spontaneous PTB is associated with decreased neonatal morbidity/mortality. Both vaginal progesterone and cerclage individually have level 1 evidence supporting benefit in prevention of PTB in pregnancies complicated by short CL, however there is a paucity of level 1 evidence regarding the potential benefit of cerclage with progesterone compared to progesterone alone for short CL ≤25mm in singletons without a history of spontaneous PTB.

Objective: We aimed to conduct a pragmatic randomized controlled trial to evaluate the additional benefit of cerclage with vaginal progesterone compared to vaginal progesterone alone in singletons without prior spontaneous PTB and with a current mid-trimester transvaginal ultrasound (TVU) CL ≤25mm STUDY DESIGN: This is a multicenter international randomized controlled trial from 09/2017-09/2023 with four sites in the United States and Italy. Singleton pregnancies without prior spontaneous PTB received TVUCL (universal) screening during mid-trimester anatomy ultrasound as part of routine care. Inclusion criteria was TVUCL≤25mm at 18 0/7 - 23 6/7 weeks. Exclusion criteria included current or planned cerclage, cervical dilation, symptoms of labor, infection, bleeding, rupture of membranes at screening. Participants were randomized 1:1 to cerclage with vaginal progesterone (200mg vaginal progesterone daily) or vaginal progesterone alone; randomization was stratified by study site and TVUCL≤15mm. Primary outcome was PTB<35 weeks by intention to treat analysis. Secondary outcomes included PTB <37,32,28,24 weeks, gestational age at delivery, latency to delivery, and neonatal outcomes. Categorical variables were compared with Pearson Chi-Square and relative risk (RR) estimate and 95% confidence interval (CI). Continuous variables compared with Mann Whitney U test. Latency to delivery and gestational age at delivery were also compared with Kaplan Meier Survival Curve. Planned enrollment was N=206 based on an estimated 0.54 relative risk with cerclage and a 34% incidence of PTB with standard care. The trial was registered on clinicaltrials.gov (NCT03251729) on June 22, 2017.

Results: Enrollment ran from September 22nd, 2017- October 31st, 2023, and it was halted early due to lagging enrollment. Ninety-three participants were randomized, three were excluded due to withdrawal (n=1) and loss to follow up (n=2). Of the 90 included in the intention to treat analysis, 43 to cerclage and progesterone, and 47 to progesterone alone. Overall, 40 (40.4%) had a TVUCL≤15mm. There was no significant difference in primary outcome PTB<35 weeks in those randomized to cerclage with progesterone vs progesterone alone: 16.3% vs 23.4%, RR 0.70 (0.30-1.63). Those randomized to cerclage with progesterone had significantly increased latency from randomization to delivery, median difference 13 (5-20) days (p=0.01), and a significantly later gestational age at delivery, median difference 1.0 (0.2-1.7) weeks (p=0.035). Kaplan Meier Survival curve also demonstrated increased latency to delivery and gestational age at delivery for cerclage with progesterone compared to progesterone alone, Mantel Cox Log Rank p<0.001 and p=0.003 respectively. These findings persisted within both subgroups of ≤15mm and at 16-25mm.

Conclusion: In singleton gestations without a prior spontaneous PTB, and a TVU CL ≤25mm before 24 weeks, cerclage with progesterone was not found to significantly reduce PTB rate, but did result in a significantly longer latency from randomization to delivery, and a significantly later gestational age at delivery, compared to progesterone alone. These results suggest the potential for benefit with cerclage and progesterone compared to progesterone alone in singletons without a prior spontaneous PTB and a short cervical length ≤25mm before 24 weeks. This trial was halted early and these findings should be confirmed in larger trial or meta-analysis.

Tweetable abstract: In singletons with short cervix and no prior spontaneous PTB cerclage with progesterone compared to progesterone alone did not reduce incidence of PTB; but those with cerclage and progesterone had increased latency to delivery and gestational age of delivery. This trial was halted early, and larger clinical trials or meta-analyses are necessary.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.40
自引率
3.20%
发文量
254
审稿时长
40 days
期刊介绍: The American Journal of Obstetrics and Gynecology (AJOG) is a highly esteemed publication with two companion titles. One of these is the American Journal of Obstetrics and Gynecology Maternal-Fetal Medicine (AJOG MFM), which is dedicated to the latest research in the field of maternal-fetal medicine, specifically concerning high-risk pregnancies. The journal encompasses a wide range of topics, including: Maternal Complications: It addresses significant studies that have the potential to change clinical practice regarding complications faced by pregnant women. Fetal Complications: The journal covers prenatal diagnosis, ultrasound, and genetic issues related to the fetus, providing insights into the management and care of fetal health. Prenatal Care: It discusses the best practices in prenatal care to ensure the health and well-being of both the mother and the unborn child. Intrapartum Care: It provides guidance on the care provided during the childbirth process, which is critical for the safety of both mother and baby. Postpartum Issues: The journal also tackles issues that arise after childbirth, focusing on the postpartum period and its implications for maternal health. AJOG MFM serves as a reliable forum for peer-reviewed research, with a preference for randomized trials and meta-analyses. The goal is to equip researchers and clinicians with the most current information and evidence-based strategies to effectively manage high-risk pregnancies and to provide the best possible care for mothers and their unborn children.
期刊最新文献
The Role of Incorporating Maternal-Fetal Medicine Physicians onto Labor and Delivery in Reducing Maternal Morbidity. Intrauterine vacuum and balloon tamponade devices have similar rates of postpartum hemorrhage control: a retrospective cohort study. Intravenous calcium during spinal anesthesia in preeclamptic women receiving magnesium therapy. Is it not Time to Propose a Maternal-Fetal Definition of Fetal Growth Restriction specifically Linked to Maternal Vascular Malperfusion of the Placenta. Letter to The Editor in response to "Oxytocin regimen used for induction of labor and pregnancy outcomes".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1